论文部分内容阅读
选取2013年9月至2015年1月超重或肥胖的2型糖尿病患者80例,随机分为观察组和对照组各40例,观察组给予利拉鲁肽治疗,对照组给予二甲双胍治疗,结果:治疗后两组FBG、2h PBG、Hb A1C、BMI、TG、CHO、LDL-C均下降,BM I、TG、减低更明显,差异FBG、2h PBG、Hb A1C、CHO、LDL-C(P>0.05)。均有不良反应,具没有统计学意义。结论:利拉鲁肽与二甲双胍应用于超重2型糖尿病均有效,利拉鲁肽在减低体重和降低TG方面更好
Eighty patients with type 2 diabetes who were overweight or obese from September 2013 to January 2015 were randomly divided into observation group (40 cases) and control group (40 cases). The observation group received liraglutide and the control group received metformin. Results: After treatment, FBG, 2h PBG, Hb A1C, BMI, TG, CHO and LDL-C in both groups were decreased, BM I and TG decreased more obviously, 0.05). Have adverse reactions, with no statistical significance. Conclusion: Both liraglutide and metformin are effective in overweight type 2 diabetes, and liraglutide is better at reducing body weight and lowering TG